HRR Reference Standards – 28‑Gene Panel for Homologous Recombination Repair Research！
Comprehensive reference material covering key HRR genes with diverse mutation types and allele frequencies.
Product Center
Product Introduce
OHomologous Recombination Repair (HRR) – 28‑Gene Reference Standard.Homologous recombination repair (HRR) is a critical pathway for DNA double‑strand break repair. Defects in HRR genes (e.g., BRCA1, BRCA2, ATM, PALB2) lead to genomic instability and are associated with breast, ovarian, prostate, pancreatic, and other cancers. Patients with HRR deficiency often benefit from PARP inhibitors and platinum‑based therapies.
CB-Gene’s HRR‑Related 28‑Gene Reference Standard (CBP90021/CBP90044) is a well‑characterized, cell‑line‑derived cocktail that mimics clinical samples. It contains all 28 HRR pathway genes (as defined by the ARIEL3 study), each carrying mutations with diverse types: missense, nonsense, insertions, deletions, splice variants, and copy number variations. The standard includes clinically annotated variants (Benign, Likely Benign, VUS, Likely Pathogenic, Pathogenic) and a wide range of allele frequencies (from 1–5% near LoD to 50–100% high frequency). It is validated by 1000x WES, 3500x targeted NGS panel, and ddPCR for select sites.
Product Advantages
Our HRR Reference Standards simulate precise variant allele frequencies (VAFs) mirroring real clinical samples.
Comprehensive Coverage
28 HRR pathway genes including BRCA1, BRCA2, ATM, ATR, BARD1, BLM, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCF, FANCI, FANCL, FANCM, MRE11A, NBN, PALB2, PPP2R2A, RAD50, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, and RPA1.
Diverse mutation types
Missense, nonsense, frameshift insertions/deletions, splice site variants, and synonymous variants.
Full clinical annotation spectrum
Includes Benign, Likely Benign, Uncertain Significance, Likely Pathogenic, and Pathogenic variants.
Wide allele frequency range
From ~1–5% (near LoD), through 10–50% (medium), up to 100% (high/ homozygous).
Multi‑platform validation
Characterized by 1000x WES, 3500x targeted NGS panel, and ddPCR for key sites.
Patent‑protected technology
Developed based on Cobioer’s patent “Standard for DNA Homologous Recombination Repair Gene Detection and Its Preparation Method”.
Application
Assay Sensitivity, Linearity & LoD Determination
Research Kit Optimization & Performance Validation
Daily Quality Control & Translational Research Integration
Company Advantage
Expertise in reference standards – CB-Gene specializes in oncology molecular diagnostics with ISO‑certified production and patented technology.
Scientific Quality Management
With our ISO9001 certification, we adhere to a stringent quality management system, ensuring that all our products meet the highest standards of accuracy, stability, and consistency.
Experienced and Skilled Team
Backed by a talented team of experts, we leverage advanced technology and extensive experience to drive innovation in molecular diagnostics, ensuring we stay at the forefront of the industry.
Comprehensive annotation
Includes benign to pathogenic variants, helping you evaluate real‑world assay performance.
Comprehensive Product Range
We offer a complete set of reference materials, including SNP, Indel, CNV, Fusion, NIPT, and more, covering a wide array of diagnostic needs and offering customized services for a variety of applications.
Contact Us
We're here to assist you! Whether you have questions about our products, services, or need technical support, our team is ready to provide you with the information you need. Reach out to us today!
FAQs
Related Blogs
Understanding NIPT Research: The Role of Reference Standards in Enhancing Testing Accuracy
In the rapid evolution of prenatal genomics, non-invasive prenatal testing (NIPT) has emerged as one of the most groundbreaking advancements. It enables fetal chromosomal screening through maternal blood sampling and analysis of cell-free DNA (cfDNA).
Read More
Fetal Fraction Matters: Enhancing NIPT Assay Performance with Matched Reference Materials
Fetal fraction (FF)—the percentage of cell-free fetal DNA in maternal plasma—is a critical factor affecting the sensitivity and reliability of non-invasive prenatal testing (NIPT).
Read More
Optimizing Cancer Genomic Testing with HRD Reference Standards: A Focus on Precision and Quality
In the field of cancer genomics research, ensuring accurate and reproducible results is critical for the development and validation of high-performance assays. As genomic technologies such as Next-Generation Sequencing (NGS) continue to evolve, the demand for reliable and standardized reference materials has grown.
Read More
Understanding HRD and its Role in Cancer Detection: A Guide for Genomic Testing Companies
Homologous Recombination Deficiency (HRD) refers to a condition where a cell's ability to repair DNA double-strand breaks via the homologous recombination repair (HRR) pathway is compromised. This deficiency can lead to genomic instability, a hallmark of many cancer types.
Read More
Get Touch With Us
Contact Info
Have questions or need assistance? We're here to help! Reach out to our team, and we'll provide the support you need.
